IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence

Status:	Recruiting
Conditions:	HIV / AIDS, HIV / AIDS
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	Any
Updated:	7/28/2018
Start Date:	February 2015
End Date:	March 2023
Contact:	Anne Coletti, MS
Email:	acoletti@fhi360.org
Phone:	919-544-7040

IMPAACT P1107: Cord Blood Transplantation With CCR5Δ32 Donor Cells in HIV-1 Infected Subjects Who Require Bone Marrow Transplantation for Any Indication and Its Observed Effects on HIV-1 Persistence

IMPAACT P1107 will describe the outcomes of HIV-infected persons, ages 12 months and older,
who undergo transplantation with CCR5Δ32 cord blood stem cells for treatment of cancer,
hematopoietic disease, or other underlying disease.

Inclusion Criteria:

- Confirmed HIV-1 infection

- 12 months of age or older

- Willing to provide written informed consent

- Pre-Transplant Cohort: Underlying disease appropriate for stem cell transplant, as
determined by the transplant team as part of standard of care.

- Pre-Transplant Cohort: Availability of an appropriately matched (as determined by the
transplant center) CCR5Δ32 cord blood unit (homozygous or heterozygous) and intention
to proceed with transplantation. NOTE: Double cord transplants are allowed. If a
double cord is used, at least one cord blood unit should be CCR5∆32 (homozygous or
heterozygous).

- Pre-Transplant Cohort: Received a CCR5Δ32 homozygous cord blood or bone marrow
transplant within the last two years.

Exclusion Criteria:

• Received, or planning to receive, more than one CCR5Δ32 homozygous cord blood or bone
marrow transplant.

We found this trial at

sites

Washington University School of Medicine

660 S Euclid Ave
Saint Louis, Missouri 63110

(314) 362-5000